In the run-up to the Paris climate change summit in November, the European Union’s chief health official warned of a looming crisis as homeopathic medicines were forced to become less affordable.
“The climate of prescription drugs is changing,” the European Medicines Agency (EMA) chief, Jean-Claude Juncker, said at a press conference in Brussels on November 7.
“I see a lot of medicines that are no longer available in the EU because the market is closed.”
In a press release, EMA warned that the EU’s healthcare system would be unable to cope with the rising demand for homeopathic drugs.
In the past year, the number of prescriptions for homeopathy pills has grown by nearly 30 percent, and the number for vitamin B12 has risen by more than 60 percent, Emas said.
“It is no longer feasible for Europe to provide all its medicines to all its people,” he said.
Since June 2018, homeopathy has become the preferred medicine of the EU and the United States.
In 2018, more than half of all prescription medicines sold in Europe were homeopathic, and homeopathy accounted for nearly half of the world’s homeopathic sales.
According to the latest figures from the European Pharmacists Association (EPA), homeopathic medicine accounted for around 7 percent of the total prescription market.
Homeopathic products account for about 5 percent of all products sold in the United Kingdom, which is the world leader in homeopathic products.
The number of homeopathic prescriptions for the US rose by more like 70 percent from 2013 to 2019, according to the EPA.
Homeopathy’s impact in the healthcare system has been more pronounced in Europe.
In 2016, homeopaths made up more than 5 percent the market in the UK, and they were responsible for more than 6 percent of prescription sales in the country, according the EMA.
This year, homebuyers in Britain are more likely to take homeopathic medication, according a study conducted by the National Centre for Homeopathic Medicine.
In a recent survey, home health care professionals in the U.K. were more likely than non-home health care practitioners to say they used homeopathic medications, and a higher percentage of people had seen a homeopathic doctor.
This is the first year in a row that the EFA has been able to report on the number and growth of homeopathy prescriptions in Europe, but it says that in 2020, the figure was only 3.5 percent.
Since 2016, the EDA has published reports on the growth in homeopathy prescribing in Europe as well as a list of the top 100 most popular homeopathic remedies in the European market.
However, in a new report, the agency says that the homeopathic market is still not sustainable.
“We are concerned that the current growth of the homeopathy industry will not be sustainable,” says EMA chief executive David Burtch.
In the future, home doctors and homeopathic doctors will need to work together to meet the growing demand for their products. “
This will put pressure on healthcare systems to cope.”
In the future, home doctors and homeopathic doctors will need to work together to meet the growing demand for their products.
In order to meet this growing demand, EFA says it will introduce the new Homeopathy Products Regulatory System (HPSRS), which will allow the regulated homeopathic industry to share information about the medicines they sell.
Homeopaths will be able to submit requests to the regulator to help it understand how they are using the medicines.
It is expected that the HPSRS will become a main source of information for the health system.
The new regulatory system is designed to enable homeopathic and homeopath products to be shared more effectively among consumers and will allow homeopathic companies to work with the EEA to establish new regulatory standards.
The regulatory framework will be established through the use of an EEA-developed “buy-in” tool that will allow for the sharing of medicines by homeopathic manufacturers with the public.
The EMA says that it will use the tool to promote the sharing and use of homeopath medicines in the community, and it will make the ECA, which oversees the regulatory system, a single central point of contact for homeopath product sharing.
The tool is expected be in place by 2018.
“HPSrs will allow us to continue to share the information we already have on the medicines we sell with the broader public, and we will also provide information on the products we do not sell to the public,” Burtches said.
This new regulatory framework is aimed at encouraging greater cooperation between the homeopath and the ELA.
The European Medicine Agency will be responsible for monitoring the new regulatory scheme.
Burtche says that, in the future and in partnership with other regulators, it is also hoped that the new framework will allow all homeopathic product manufacturers to use the regulatory tool for market access.